RNA編集技術市場- 世界の産業規模、シェア、動向、機会、予測、RNAタイプ別、用途別、技術別、地域別、競合別、2019年～2029年

世界のRNA編集技術市場は、2023年に2億6,128万米ドルと評価され、2029年までのCAGRは6.94%で、予測期間中に目覚ましい成長を予測されます。

世界のRNA編集技術市場には、治療、調査、診断用途のためにRNA分子を正確に改変するように設計された革新的なツールや技術の多様な配列が含まれます。RNA編集技術はRNA配列の標的改変を可能にし、遺伝子変異の修正、遺伝子発現の調節、新規RNAベース治療法の開発など、これまでにない機会を提供します。同市場の主要企業は、CRISPRベースのRNA編集、RNA干渉（RNAi）、RNA塩基編集などの技術を進歩させ、遺伝性疾患、がん、感染症などの幅広い疾患に対処しています。市場を牽引しているのは、研究投資の増加、個別化医療に対する需要の高まり、バイオテクノロジーや医療のさまざまな分野におけるRNA編集技術の応用拡大です。技術の進歩が進み、RNA生物学に対する理解が深まるにつれて、世界のRNA編集技術市場は今後数年間で大きな成長と革新を遂げる態勢が整っています。

主な市場促進要因

CRISPRベースのRNA編集の進歩

RNA治療薬の急速な拡大

RNA編集研究への投資の増加

ゲノム編集用途の拡大

主な市場課題

オフターゲット効果と特異性に関する懸念

RNA編集における精度と制御

主な市場動向

診断におけるRNA編集の出現

RNAベースの治療に対する規制支援

セグメント別の洞察

RNAタイプ別の洞察

用途別の洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のRNA編集技術市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • RNAタイプ別（メッセンジャーRNA改変、転移RNA改変、リボソームRNA改変）
  • 用途別（がん、遺伝子疾患、一時的疾患）
  • 技術別（挿入／欠失、脱アミノ化）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第6章 北米のRNA編集技術市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • RNAタイプ別
  • 用途別
  • 技術別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のRNA編集技術市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • RNAタイプ別
  • 用途別
  • 技術別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のRNA編集技術市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • RNAタイプ別
  • 用途別
  • 技術別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のRNA編集技術市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • RNAタイプ別
  • 用途別
  • 技術別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのRNA編集技術市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • RNAタイプ別
  • 用途別
  • 技術別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併買収（もしあれば）
• 製品上市（もしあれば）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• ProQR Therapeutics NV
• Sirna Therapeutics, Inc.
• Shape Therapeutics, Inc.
• Korro Bio, Inc.
• Beam Therapeutics, Inc.
• QIAGEN N.V.
• UniQure NV（UniQure）
• LAVA Therapeutics N.V.
• argenx SE
• Arrowhead Pharmaceuticals, Inc.

第15章 戦略的提言

第16章 免責事項

Global RNA Editing Technologies Market was valued at USD 261.28 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.94% through 2029. The Global RNA Editing Technologies Market encompasses a diverse array of innovative tools and techniques designed to precisely modify RNA molecules for therapeutic, research, and diagnostic applications. RNA editing technologies enable targeted alterations to RNA sequences, offering unprecedented opportunities to correct genetic mutations, modulate gene expression, and develop novel RNA-based therapies. Key players in the market are advancing technologies such as CRISPR-based RNA editing, RNA interference (RNAi), and RNA base editing to address a wide range of diseases, including genetic disorders, cancer, and infectious diseases. The market is driven by increasing research investments, growing demand for personalized medicine, and the expanding applications of RNA editing technologies across various fields of biotechnology and medicine. With ongoing advancements in technology and increasing understanding of RNA biology, the Global RNA Editing Technologies Market is poised for significant growth and innovation in the coming years.

Key Market Drivers

Advancements in CRISPR-Based RNA Editing

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has heralded a paradigm shift in the realm of RNA editing, fundamentally altering our ability to precisely modify RNA sequences. This revolutionary technology empowers researchers and scientists with unprecedented control over RNA molecules, enabling targeted alterations with unrivaled precision. Among the arsenal of CRISPR-based tools, CRISPR-Cas13 and CRISPR-CasRx stand out for their exceptional specificity and efficiency in homing in on RNA targets for editing. The advent of CRISPR-based RNA editing has not only transformed basic research but has also catalyzed breakthroughs in therapeutic development, diagnostic applications, and functional genomics. By harnessing the power of CRISPR technology, researchers can manipulate RNA sequences with unparalleled accuracy, opening new avenues for addressing a myriad of diseases at the genetic level.

As the field of RNA editing continues to evolve, ongoing research endeavors are dedicated to refining and enhancing CRISPR-based RNA editing platforms. Efforts are focused on optimizing delivery mechanisms to ensure efficient and precise targeting of RNA molecules within cells. Researchers are striving to expand the scope of CRISPR-based RNA editing by augmenting its targeting capabilities and improving its versatility. These advancements hold tremendous promise for the future of therapeutic interventions, particularly in the realms of genetic disorders and infectious diseases. The enhanced precision and versatility of CRISPR-based RNA editing technologies are anticipated to unlock novel therapeutic strategies, offering hope for patients afflicted with previously untreatable conditions.

Rapid Expansion of RNA Therapeutics

The field of RNA therapeutics has witnessed significant growth in recent years, fueled by advances in RNA editing technologies. RNA-based therapeutics, including mRNA vaccines, RNA interference (RNAi) therapeutics, and RNA editing therapies, hold immense promise for treating a wide range of diseases, from cancer and genetic disorders to infectious diseases and neurological conditions.

RNA editing technologies play a crucial role in the development of RNA therapeutics by enabling precise modifications to RNA sequences to correct disease-causing mutations or modulate gene expression. As the clinical pipeline of RNA therapeutics continues to expand, driven by the success of mRNA vaccines and the growing understanding of RNA biology, the demand for RNA editing technologies is expected to surge.

Growing Investments in RNA Editing Research

The increasing interest and investment in RNA editing research from both public and private sectors are driving innovation and technological advancements in the field. Funding agencies, academic institutions, biotechnology companies, and pharmaceutical firms are allocating substantial resources to support RNA editing research initiatives, including basic research, preclinical studies, and clinical trials.

These investments are fueling the development of novel RNA editing technologies, the exploration of new therapeutic applications, and the translation of RNA editing-based therapies from the bench to the bedside. Collaborations and partnerships between academia and industry are fostering knowledge exchange, resource sharing, and technology transfer, accelerating the pace of innovation in RNA editing technologies.

Expansion of Genome Editing Applications

While CRISPR-based genome editing initially focused on DNA manipulation, recent advancements have extended its utility to RNA editing applications. Genome editing technologies, such as base editors and prime editors, can be repurposed for RNA editing by targeting RNA molecules instead of genomic DNA.

The versatility of genome editing platforms in RNA manipulation opens up new avenues for RNA-based therapies, gene regulation studies, and functional genomics research. The ability to edit RNA sequences directly offers advantages in terms of temporal control, reversibility, and reduced off-target effects compared to DNA editing approaches. As a result, the expansion of genome editing applications to include RNA editing is driving the growth of the RNA editing technologies market.

Key Market Challenges

Off-Target Effects and Specificity Concerns

A major challenge in the development and adoption of RNA editing technologies is the potential for off-target effects and concerns regarding specificity. Despite advancements in CRISPR-based RNA editing tools, such as CRISPR-Cas13 and CRISPR-CasRx, off-target editing events can still occur, leading to unintended modifications in RNA sequences. These off-target effects pose safety risks and may result in unforeseen consequences, including cellular toxicity and genetic instability. Addressing off-target effects requires ongoing research efforts to enhance the specificity of RNA editing platforms and minimize unintended alterations to non-target RNA molecules. Strategies such as engineering more precise guide RNAs, optimizing delivery methods, and implementing bioinformatics tools for off-target prediction and validation are being explored to mitigate this challenge. Improving our understanding of RNA biology and the mechanisms underlying off-target editing events is essential for developing safer and more reliable RNA editing technologies.

Precision and Control in RNA Editing

Achieving precise and controlled RNA editing presents a significant challenge in the global RNA editing technologies market. While CRISPR-based RNA editing tools offer remarkable precision, achieving single-nucleotide resolution and site-specific modifications remains challenging. Controlling the timing and duration of RNA editing activity in vivo is crucial for minimizing off-target effects and maximizing therapeutic efficacy.

Strategies to enhance precision and control in RNA editing include the development of novel CRISPR variants with improved editing fidelity, the optimization of guide RNA design to increase specificity, and the implementation of inducible or regulatable editing systems for temporal control. Leveraging insights from RNA biology and RNA-protein interactions can inform the design of RNA editing tools that exhibit greater selectivity and predictability in targeting RNA molecules.

Key Market Trends

Emergence of RNA Editing in Diagnostics

RNA editing technologies are increasingly being utilized in diagnostic applications for detecting and characterizing RNA modifications associated with disease states. RNA biomarkers, such as RNA editing events, alternative splicing patterns, and expression levels of non-coding RNAs, hold diagnostic value for various diseases, including cancer, neurodegenerative disorders, and viral infections.

Advances in RNA sequencing technologies, bioinformatics tools, and machine learning algorithms have facilitated the identification and analysis of RNA biomarkers in clinical samples. RNA editing signatures detected in patient-derived RNA sequences can provide valuable insights into disease progression, treatment response, and patient prognosis. Consequently, the integration of RNA editing technologies into diagnostic workflows is driving innovation in precision medicine and personalized healthcare.

Regulatory Support for RNA-Based Therapies

Regulatory agencies worldwide are recognizing the potential of RNA-based therapies, including RNA editing technologies, in addressing unmet medical needs and improving patient outcomes. Efforts to streamline regulatory pathways, provide guidance on product development, and facilitate expedited approvals for RNA therapeutics are fostering a favorable environment for innovation and investment in the RNA editing technologies market.

Regulatory frameworks, such as the U.S. Food and Drug Administration's (FDA) RNAi Guidance and the European Medicines Agency's (EMA) guidelines on RNA-based therapeutics, offer clear pathways for the development and regulatory approval of RNA editing-based therapies. These regulatory initiatives provide industry stakeholders with confidence and certainty in navigating the regulatory landscape, accelerating the translation of RNA editing technologies from research to clinical applications.

Segmental Insights

Type of RNA Insights

Based on the type of RNA, Messenger RNA (mRNA) Modification is currently dominating the RNA Editing Technologies Market. mRNA plays a central role in the process of gene expression by conveying genetic information from the DNA to the ribosomes, where it is translated into proteins. RNA modifications, including methylation, and adenosine deamination, regulate mRNA stability, splicing, localization, and translation efficiency, influencing cellular processes and gene expression dynamics.

The emergence of mRNA modification as a dominant force in the RNA Editing Technologies Market is driven by several factors. mRNA modifications are increasingly recognized as critical regulators of gene expression and cellular function, with implications for various physiological and pathological processes, including development, cancer, and neurodegenerative diseases. As researchers unravel the complexity of mRNA modifications and their impact on cellular biology, there is growing interest in developing technologies to manipulate and study these modifications in a controlled manner. mRNA modification technologies offer promising opportunities for therapeutic intervention in the treatment of genetic disorders, cancer, and other diseases. RNA editing tools, such as CRISPR-based RNA editors and RNA-modifying enzymes, enable precise modifications to mRNA sequences, allowing for the correction of disease-causing mutations, modulation of gene expression, and targeted delivery of therapeutic payloads. These advancements hold potential for the development of RNA-based therapies that harness the power of mRNA modifications to restore normal cellular function and treat a wide range of diseases at the molecular level.

Application Insights

Based on the application segment, cancer stands out as the dominant focus in the Global RNA Editing Technologies Market. The pervasiveness and complexity of cancer have fuelled extensive research efforts aimed at understanding the molecular mechanisms underlying oncogenesis and developing innovative therapeutic strategies. RNA editing technologies offer promising avenues for precision medicine approaches in cancer treatment by targeting aberrant RNA molecules associated with tumour growth, metastasis, and therapy resistance.

The dominance of cancer in driving the Global RNA Editing Technologies Market is underscored by several key factors. RNA editing alterations are increasingly recognized as critical drivers of oncogenesis and tumor progression. Dysregulated RNA editing enzymes, such as ADARs (adenosine deaminases acting on RNA) and APOBECs (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like), contribute to the generation of cancer-associated RNA editing signatures, including A-to-I (adenosine-to-inosine) and C-to-U (cytidine-to-uridine) editing events, which modulate gene expression, RNA stability, and protein function in cancer cells. RNA editing technologies offer innovative approaches for targeting cancer-specific RNA alterations and vulnerabilities. CRISPR-based RNA editing tools, RNA-modifying enzymes, and RNA-targeting small molecules enable precise manipulation of RNA molecules implicated in cancer pathogenesis, providing opportunities for therapeutic intervention. RNA editing strategies can be tailored to correct cancer-driving mutations, disrupt oncogenic RNA modifications, or modulate the expression of key cancer-related genes, thereby suppressing tumor growth and enhancing sensitivity to conventional cancer therapies.

Regional Insights

North America emerges as the dominant region in the Global RNA Editing Technologies Market. Several factors contribute to North America's dominance in this market segment. North America boasts a robust research and development infrastructure, comprising renowned academic institutions, biotechnology hubs, and pharmaceutical companies at the forefront of RNA editing technologies. These institutions drive innovation and technological advancements in RNA editing research, fostering a dynamic ecosystem for collaboration and discovery. North America benefits from significant investments in healthcare and biotechnology research, supported by government funding agencies, private foundations, and venture capital firms. These investments fuel the development of novel RNA editing technologies, the translation of research findings into clinical applications, and the commercialization of RNA editing-based therapies and diagnostics.

Regulatory frameworks in North America provide clear pathways for the development, approval, and commercialization of RNA editing technologies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada have established guidelines and expedited review processes for RNA editing-based therapies, facilitating market access and adoption.

Key Market Players

ProQR Therapeutics NV

Sirna Therapeutics, Inc.

Shape Therapeutics, Inc.

Korro Bio, Inc.

Beam Therapeutics, Inc.

QIAGEN N.V.

UniQure NV (UniQure)

LAVA Therapeutics N.V.

argenx SE

Arrowhead Pharmaceuticals, Inc.

Report Scope:

In this report, the Global RNA Editing Technologies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Editing Technologies Market,By Type of RNA:

• Messenger RNA Modification
• Transfer RNA Modification
• Ribosomal RNA Modification

RNA Editing Technologies Market,By Application:

• Cancer
• Genetic Disorders
• Temporary Maladies

RNA Editing Technologies Market,By Technique:

• Insertion/ Deletion
• Deamination

RNA Editing Technologies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Editing Technologies Market.

Available Customizations:

Global RNA Editing Technologies market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global RNA Editing Technologies Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Type of RNA (Messenger RNA Modification, Transfer RNA Modification, Ribosomal RNA Modification)
  • 5.2.2.By Application (Cancer, Genetic Disorders, Temporary Maladies)
  • 5.2.3.By Technique (Insertion/ Deletion, Deamination)
  • 5.2.4.By Region
  • 5.2.5.By Company (2023)
• 5.3.Market Map

6.North America RNA Editing Technologies Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.ByType of RNA
  • 6.2.2.By Application
  • 6.2.3.By Technique
  • 6.2.4.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States RNA Editing Technologies Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Type of RNA
      • 6.3.1.2.2.By Application
      • 6.3.1.2.3.By Technique
  • 6.3.2.Canada RNA Editing Technologies Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Type of RNA
      • 6.3.2.2.2.By Application
      • 6.3.2.2.3.By Technique
  • 6.3.3.Mexico RNA Editing Technologies Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Type of RNA
      • 6.3.3.2.2.By Application
      • 6.3.3.2.3.By Technique

7.Europe RNA Editing Technologies Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Type of RNA
  • 7.2.2.By Application
  • 7.2.3.By Technique
  • 7.2.4.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.Germany RNA Editing Technologies Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Type of RNA
      • 7.3.1.2.2.By Application
      • 7.3.1.2.3.By Technique
  • 7.3.2.United Kingdom RNA Editing Technologies Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Type of RNA
      • 7.3.2.2.2.By Application
      • 7.3.2.2.3.By Technique
  • 7.3.3.Italy RNA Editing Technologies Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecasty
      • 7.3.3.2.1.By Type of RNA
      • 7.3.3.2.2.By Application
      • 7.3.3.2.3.By Technique
  • 7.3.4.France RNA Editing Technologies Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Type of RNA
      • 7.3.4.2.2.By Application
      • 7.3.4.2.3.By Technique
  • 7.3.5.Spain RNA Editing Technologies Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Type of RNA
      • 7.3.5.2.2.By Application
      • 7.3.5.2.3.By Technique

8.Asia-Pacific RNA Editing Technologies Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Type of RNA
  • 8.2.2.By Application
  • 8.2.3.By Technique
  • 8.2.4.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China RNA Editing Technologies Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Type of RNA
      • 8.3.1.2.2.By Application
      • 8.3.1.2.3.By Technique
  • 8.3.2.India RNA Editing Technologies Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Type of RNA
      • 8.3.2.2.2.By Application
      • 8.3.2.2.3.By Technique
  • 8.3.3.Japan RNA Editing Technologies Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Type of RNA
      • 8.3.3.2.2.By Application
      • 8.3.3.2.3.By Technique
  • 8.3.4.South Korea RNA Editing Technologies Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Type of RNA
      • 8.3.4.2.2.By Application
      • 8.3.4.2.3.By Technique
  • 8.3.5.Australia RNA Editing Technologies Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Type of RNA
      • 8.3.5.2.2.By Application
      • 8.3.5.2.3.By Technique

9.South America RNA Editing Technologies Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Type of RNA
  • 9.2.2.By Application
  • 9.2.3.By Technique
  • 9.2.4.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil RNA Editing Technologies Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Type of RNA
      • 9.3.1.2.2.By Application
      • 9.3.1.2.3.By Technique
  • 9.3.2.Argentina RNA Editing Technologies Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Type of RNA
      • 9.3.2.2.2.By Application
      • 9.3.2.2.3.By Technique
  • 9.3.3.Colombia RNA Editing Technologies Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Type of RNA
      • 9.3.3.2.2.By Application
      • 9.3.3.2.3.By Technique

10.Middle East and Africa RNA Editing Technologies Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Type of RNA
  • 10.2.2.By Application
  • 10.2.3.By Technique
  • 10.2.4.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa RNA Editing Technologies Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Type of RNA
      • 10.3.1.2.2.By Application
      • 10.3.1.2.3.By Technique
  • 10.3.2.Saudi Arabia RNA Editing Technologies Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Type of RNA
      • 10.3.2.2.2.By Application
      • 10.3.2.2.3.By Technique
  • 10.3.3.UAE RNA Editing Technologies Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Type of RNA
      • 10.3.3.2.2.By Application
      • 10.3.3.2.3.By Technique

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Merger Acquisition (If Any)
• 12.2.Product Launches (If Any)
• 12.3.Recent Developments

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Products

14.Competitive Landscape

• 14.1.ProQR Therapeutics NV
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Products Services
  • 14.1.4.Financials (As Reported)
  • 14.1.5.Recent Developments
  • 14.1.6.Key Personnel Details
  • 14.1.7.SWOT Analysis
• 14.2.Sirna Therapeutics, Inc.
• 14.3.Shape Therapeutics, Inc.
• 14.4.Korro Bio, Inc.
• 14.5.Beam Therapeutics, Inc.
• 14.6.QIAGEN N.V.
• 14.7.UniQure NV (UniQure)
• 14.8.LAVA Therapeutics N.V.
• 14.9.argenx SE
• 14.10.Arrowhead Pharmaceuticals, Inc.

15.Strategic Recommendations

16.About Us Disclaimer